By: Daniel Trecroci
The U.S. Food and Drug Administration announced on October 11, 2002, that it had approved Avandamet for the treatment of type 2 diabetes.
Manufactured by GlaxoSmithKline, the drug is the first to combine Avandia (rosiglitazone), a drug that directly targets insulin resistance, with metformin, a drug that works to reduce the amount of glucose produced by the liver.
In an October 11 news release from GlaxoSmithKline, Barry Goldstein, MD, PhD, director of the division of endocrinology, diabetes and metabolic diseases at Thomas Jefferson University in Philadelphia, Pennsylvania, noted that the combination of Avandia and metformin provides two different, yet complementary mechanisms of action to manage diabetes.
“The two medications, when used in combination, target core metabolic defects to help achieve better blood-glucose control than metformin alone, making this an important option for patients with type 2.”